![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » U.S. Supreme Court Denies Amarin, AbbVie Patent Appeals
U.S. Supreme Court Denies Amarin, AbbVie Patent Appeals
![Denied - Denies](https://www.fdanews.com/ext/resources/test/Drug-Images4/Denies-Denied.gif?t=1624482464&width=430)
June 24, 2021
The Supreme Court this week declined to hear two pharmaceutical patent cases.
The court rejected Amarin’s try at rejuvenating its patents on its fish-oil based drug Vascepa (icosapent ethyl). A lower court had ruled in March 2020 that the company’s patents were invalid following a challenge by two generic drug companies, Hikma Pharmaceuticals and Dr. Reddy’s Laboratories.
The Supreme Court also turned away an appeal from AbbVie of a 2011 lower court ruling that the company violated federal antitrust law by pursuing a sham patent complaint against Perrigo.
The court denied that appeal and left intact the court ruling that AbbVie’s complaint against Perrigo was filed to delay a proposed generic version of AbbVie’s testosterone drug, AndroGel.
Upcoming Events
-
21Oct